Kamada Secures $10-$14 Million Extension for Canadian Plasma-Derived Products Supply
I'm PortAI, I can summarize articles.
Kamada Ltd. has secured a two-year extension of a supply tender from Canadian Blood Services for four plasma-derived products, valued at $10-$14 million. This extension ensures sales of $5.0-$7.0 million annually from Q2 2026 to Q1 2028. Kamada maintains its 2025 revenue guidance of $178-$182 million and adjusted EBITDA of $40-$44 million, projecting double-digit growth in 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments